NorthWest Biotherapeutics Inc (NWBO)

[DocLee]

2 LIES, Hygro, in 1 sentence - pretty good going even for you.

PFS was the PRIMARY endpoint of the trial and DCVax-L failed to meet it.

Progression-free Survival (PFS) was an INITIAL endpoint of the trial but it was found to be indistinguishable from a strong immunological response with the technology available at the time and so had to be abandoned. It was not DCVax-L that failed, it was the technology that failed, as you undoubtedly know.

You are not making simple mistakes in this regard; you are deliberately trying to mislead others by the repetition of egregious falsehoods, ie YOU ARE AN OUT AND OUT LIAR.